BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Fundamental Analysis

NASDAQ:BMRN • US09061G1013

59.87 USD
-0.07 (-0.12%)
At close: Feb 13, 2026
59.87 USD
0 (0%)
After Hours: 2/13/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

BMRN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 522 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making BMRN a very profitable company, without any liquidiy or solvency issues. BMRN is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make BMRN suitable for value and quality investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year BMRN was profitable.
  • In the past year BMRN had a positive cash flow from operations.
  • Of the past 5 years BMRN 4 years were profitable.
  • Each year in the past 5 years BMRN had a positive operating cash flow.
BMRN Yearly Net Income VS EBIT VS OCF VS FCFBMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

1.2 Ratios

  • BMRN has a better Return On Assets (6.83%) than 92.53% of its industry peers.
  • BMRN's Return On Equity of 8.59% is amongst the best of the industry. BMRN outperforms 91.95% of its industry peers.
  • The Return On Invested Capital of BMRN (7.69%) is better than 93.87% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for BMRN is significantly below the industry average of 18.26%.
  • The last Return On Invested Capital (7.69%) for BMRN is above the 3 year average (3.73%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 6.83%
ROE 8.59%
ROIC 7.69%
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
BMRN Yearly ROA, ROE, ROICBMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

1.3 Margins

  • BMRN's Profit Margin of 16.82% is amongst the best of the industry. BMRN outperforms 92.53% of its industry peers.
  • BMRN has a better Operating Margin (20.21%) than 94.44% of its industry peers.
  • The Gross Margin of BMRN (81.32%) is better than 85.25% of its industry peers.
  • In the last couple of years the Gross Margin of BMRN has remained more or less at the same level.
Industry RankSector Rank
OM 20.21%
PM (TTM) 16.82%
GM 81.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
BMRN Yearly Profit, Operating, Gross MarginsBMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • BMRN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, BMRN has more shares outstanding
  • Compared to 5 years ago, BMRN has more shares outstanding
  • The debt/assets ratio for BMRN has been reduced compared to a year ago.
BMRN Yearly Shares OutstandingBMRN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
BMRN Yearly Total Debt VS Total AssetsBMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 5.62 indicates that BMRN is not in any danger for bankruptcy at the moment.
  • BMRN's Altman-Z score of 5.62 is fine compared to the rest of the industry. BMRN outperforms 74.14% of its industry peers.
  • The Debt to FCF ratio of BMRN is 0.72, which is an excellent value as it means it would take BMRN, only 0.72 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.72, BMRN belongs to the top of the industry, outperforming 94.25% of the companies in the same industry.
  • BMRN has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
  • BMRN has a Debt to Equity ratio of 0.10. This is in the lower half of the industry: BMRN underperforms 61.88% of its industry peers.
  • Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.72
Altman-Z 5.62
ROIC/WACC0.93
WACC8.26%
BMRN Yearly LT Debt VS Equity VS FCFBMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

  • BMRN has a Current Ratio of 4.83. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
  • BMRN's Current ratio of 4.83 is in line compared to the rest of the industry. BMRN outperforms 55.17% of its industry peers.
  • A Quick Ratio of 3.10 indicates that BMRN has no problem at all paying its short term obligations.
  • With a Quick ratio value of 3.10, BMRN is not doing good in the industry: 61.11% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 4.83
Quick Ratio 3.1
BMRN Yearly Current Assets VS Current LiabilitesBMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 52.00% over the past year.
  • Looking at the last year, BMRN shows a quite strong growth in Revenue. The Revenue has grown by 12.39% in the last year.
  • The Revenue has been growing by 10.86% on average over the past years. This is quite good.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%

3.2 Future

  • Based on estimates for the next years, BMRN will show a very strong growth in Earnings Per Share. The EPS will grow by 22.59% on average per year.
  • The Revenue is expected to grow by 8.09% on average over the next years. This is quite good.
EPS Next Y22.03%
EPS Next 2Y41.64%
EPS Next 3Y34.83%
EPS Next 5Y22.59%
Revenue Next Year12.66%
Revenue Next 2Y11.16%
Revenue Next 3Y10.76%
Revenue Next 5Y8.09%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BMRN Yearly Revenue VS EstimatesBMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B
BMRN Yearly EPS VS EstimatesBMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 22.51, which indicates a rather expensive current valuation of BMRN.
  • Based on the Price/Earnings ratio, BMRN is valued cheaper than 94.64% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of BMRN to the average of the S&P500 Index (26.68), we can say BMRN is valued inline with the index average.
  • Based on the Price/Forward Earnings ratio of 13.50, the valuation of BMRN can be described as correct.
  • Based on the Price/Forward Earnings ratio, BMRN is valued cheaper than 96.74% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of BMRN to the average of the S&P500 Index (28.06), we can say BMRN is valued rather cheaply.
Industry RankSector Rank
PE 22.51
Fwd PE 13.5
BMRN Price Earnings VS Forward Price EarningsBMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BMRN is valued cheaper than 95.21% of the companies in the same industry.
  • BMRN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BMRN is cheaper than 97.32% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.93
EV/EBITDA 14.68
BMRN Per share dataBMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • BMRN has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as BMRN's earnings are expected to grow with 34.83% in the coming years.
PEG (NY)1.02
PEG (5Y)N/A
EPS Next 2Y41.64%
EPS Next 3Y34.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BMRN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOMARIN PHARMACEUTICAL INC

NASDAQ:BMRN (2/13/2026, 8:00:01 PM)

After market: 59.87 0 (0%)

59.87

-0.07 (-0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-27
Earnings (Next)02-25
Inst Owners97.82%
Inst Owner Change0.78%
Ins Owners0.64%
Ins Owner Change-0.95%
Market Cap11.50B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts81.25
Price Target94.32 (57.54%)
Short Float %3.88%
Short Ratio2.64
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)2.44%
PT rev (3m)-1.45%
EPS NQ rev (1m)-36.59%
EPS NQ rev (3m)-35.34%
EPS NY rev (1m)-10.07%
EPS NY rev (3m)-11.2%
Revenue NQ rev (1m)0.45%
Revenue NQ rev (3m)0.28%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)0.19%
Valuation
Industry RankSector Rank
PE 22.51
Fwd PE 13.5
P/S 3.72
P/FCF 13.93
P/OCF 12.58
P/B 1.9
P/tB 2.04
EV/EBITDA 14.68
EPS(TTM)2.66
EY4.44%
EPS(NY)4.43
Fwd EY7.41%
FCF(TTM)4.3
FCFY7.18%
OCF(TTM)4.76
OCFY7.95%
SpS16.11
BVpS31.53
TBVpS29.29
PEG (NY)1.02
PEG (5Y)N/A
Graham Number43.44
Profitability
Industry RankSector Rank
ROA 6.83%
ROE 8.59%
ROCE 9.17%
ROIC 7.69%
ROICexc 9.82%
ROICexgc 10.68%
OM 20.21%
PM (TTM) 16.82%
GM 81.32%
FCFM 26.69%
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.72
Debt/EBITDA 0.84
Cap/Depr 106.6%
Cap/Sales 2.85%
Interest Coverage 85.91
Cash Conversion 129.08%
Profit Quality 158.68%
Current Ratio 4.83
Quick Ratio 3.1
Altman-Z 5.62
F-Score8
WACC8.26%
ROIC/WACC0.93
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y22.03%
EPS Next 2Y41.64%
EPS Next 3Y34.83%
EPS Next 5Y22.59%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.66%
Revenue Next 2Y11.16%
Revenue Next 3Y10.76%
Revenue Next 5Y8.09%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.1%
EBIT Next 3Y41.17%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%

BIOMARIN PHARMACEUTICAL INC / BMRN FAQ

Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?

ChartMill assigns a fundamental rating of 6 / 10 to BMRN.


What is the valuation status for BMRN stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.


Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?

BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 7 / 10.


What is the financial health of BIOMARIN PHARMACEUTICAL INC (BMRN) stock?

The financial health rating of BIOMARIN PHARMACEUTICAL INC (BMRN) is 7 / 10.


What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?

The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 22.03% in the next year.